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Background:  Survival with left ventricular assist devices (LVAD) has improved, but those with an implanted LVAD are still eligible for 30 days of 
elective UNOS (United Network of Organ Sharing) 1A listing time. It is questionable whether the risk among those supported with LVADs is equal to 
the risk among those supported medically.
Methods:  We used data provided by the Scientific Registry of Transplant Recipients to analyze the mortality among subgroups of patients listed 1A. 
The groups included 1A registrants with implanted and uncomplicated LVAD support (group A, n=1,442), VADs with complications (group B, n=743) 
or medical support (group C, n=11,000). We used extended Cox models to assess the likelihood of death or delisting as too ill among patients 
actively listed 1A. Mortality after transplant was measured using cumulative mortality.
Results:  The use of continuous flow LVADs increased over the time period of observation from 17% in 2004 to 44% in 2008. While listed 1A, 
those in group C had a hazard ratio (HR) of 2.9 compared to group A (p=0.0029). Those in group C had a HR of 1.4 compared to those in group B 
(p=0.17). Mortality up to 2 years after transplantation was worse in group A versus group C (HR 1.6, p=0.004) and in group B versus group C (HR 
1.5, p=0.007). There was an increase in late mortality (after 180 days) among groups A and B that accounted for the decrease in survival post-
transplant.
Conclusions:  Among UNOS 1A registrants, those with uncomplicated LVAD support using elective 1A time are at a lower risk of dying than those 
managed medically. 1A registrants with LVAD complications have a comparable mortality to those managed medically. Transplant survival after 
LVAD support, with or without complications, appears worse compared to medical support alone before transplant. UNOS 1A registrants who are 
supported medically may receive the greatest effectiveness from transplantation.
